Mohammad Memarian
, Rahimeh Eskandarian
* 1 Clinical Research Development Unit, Kowsar Educational, Research and Therapeutic Hospital, Semnan University of Medical Sciences, Semnan, Iran
Abstract
The landscape of pulmonary hypertension (PAH) treatment is evolving, with SGLT2 inhibitors being recognized as a potential fourth treatment pathway alongside traditional therapies. Their incorporation into treatment strategies for PAH could represent a significant shift in management approaches.
Implication for health policy/practice/research/medical education:
Sodium-glucose co-transporter 2 (SGLT2) inhibitors show promise in treating pulmonary hypertension (PAH) through their multifaceted effects on metabolism, vascular function, and hemodynamics.
Please cite this paper as: Memarian M, Eskandarian R. SGLT2 inhibitors for the treatment of pulmonary hypertension; new trends. J Renal Inj Prev. 2025; 14(3): e38409. doi: 10.34172/jrip.2025.38409.